BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21933385)

  • 1. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
    Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
    Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.
    Golden JW; Hooper JW
    Clin Vaccine Immunol; 2010 Nov; 17(11):1656-65. PubMed ID: 20844086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
    Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.
    Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP
    PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
    Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
    J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine.
    Golden JW; Hooper JW
    Virology; 2008 Jul; 377(1):19-29. PubMed ID: 18482742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
    Fogg CN; Americo JL; Earl PL; Resch W; Aldaz-Carroll L; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2008 Aug; 82(16):8022-9. PubMed ID: 18524827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.
    Benhnia MR; Maybeno M; Blum D; Aguilar-Sino R; Matho M; Meng X; Head S; Felgner PL; Zajonc DM; Koriazova L; Kato S; Burton DR; Xiang Y; Crowe JE; Peters B; Crotty S
    J Virol; 2013 Feb; 87(3):1569-85. PubMed ID: 23152530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
    Shinoda K; Wyatt LS; Irvine KR; Moss B
    Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.
    Hooper JW; Golden JW; Ferro AM; King AD
    Vaccine; 2007 Feb; 25(10):1814-23. PubMed ID: 17240007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
    Hooper JW; Custer DM; Thompson E
    Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
    Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
    Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
    McCausland MM; Benhnia MR; Crickard L; Laudenslager J; Granger SW; Tahara T; Kubo R; Koriazova L; Kato S; Crotty S
    Antivir Ther; 2010; 15(4):661-75. PubMed ID: 20587859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.
    Xu C; Meng X; Yan B; Crotty S; Deng J; Xiang Y
    Virology; 2011 Sep; 418(1):67-73. PubMed ID: 21810533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
    Kaever T; Matho MH; Meng X; Crickard L; Schlossman A; Xiang Y; Crotty S; Peters B; Zajonc DM
    J Virol; 2016 May; 90(9):4334-4345. PubMed ID: 26889021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.